Lv1
30 积分 2021-10-19 加入
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
12天前
已完结
Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?
1个月前
已完结
Pathological features of rectal cancer after preoperative radiochemotherapy
1个月前
已完结
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Surgical treatment of disseminated peritoneal metastases from urological cancer: results from a prospective study
1个月前
已完结
The importance of measuring baseline tumour volume (or alternatively tumour length along with its rectal circumferential extent) in the watch-and-wait strategy in rectal cancer: a review
2个月前
已完结
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer
2个月前
已完结
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial
3个月前
已完结
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer
4个月前
已完结
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
4个月前
已完结
皖公网安备34019202002308
